secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001104659-25-119654
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces City of Hope IST testing PEDMARK in adult testicular germ cell tumors
--------------------------------------------------------------------------------

- Phase I study (NCT07218913) evaluating PEDMARK to prevent cisplatin-induced ototoxicity in adults with stage II-III metastatic testicular germ cell tumors.
- Principal investigator: Alexander Chehrazi-Raffle, M.D., at City of Hope, Duarte, CA.
- PEDMARK is currently approved for pediatric patients with localized solid tumors; this expands investigation into adult metastatic setting.
- Multiple other investigator-initiated studies submitted or in advanced contracting stages.
- Fennec's CMO cites need for hearing protection in cisplatin-treated survivors; study aims to change standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465925119654/0001104659-25-119654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465925119654/fencf-20251209x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-119654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer